Is It Too Late to Buy Viking Therapeutics Stock?

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech that rose in prominence this year. The drugmaker's shares are up by nearly 200% since January.However, while many investors are excited about Viking's prospects, others worry they have already missed the boat. How much upside does a clinical-stage biotech with a market cap of $6.3 billion have? Is it too late to invest in Viking Therapeutics, or do the company's shares remain attractive?There could be plenty of upside for Viking Therapeutics. If the drugmaker's promising phase 2 assets earn approval without a hitch, its stock price will likely soar even more. The issue is whether the upside potential outweighs the risk. One (very) imperfect way to determine whether Viking Therapeutics is overvalued is to compare it with other mid-cap drugmakers.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool